Case CCC Immune Oncology Program member George (Changchun) Deng, MD, PhD, discusses the rapidly evolving treatment landscape for follicular lymphoma, including the growing role of bispecific antibodies and other immune-based therapies that could reduce reliance on traditional chemotherapy.
Hear his perspective on where the field is headed—and the questions researchers are working to answer next.